Anthropic reveals how teachers are using AI

September 29, 2025

Anthropic has launched testing of a new Chrome extension called “Claude for Chrome”, which gives the assistant agentic control over the user’s browser. The goal is to explore how AI can browse and perform actions online more safely, especially after issues other AI-powered browsers have faced.

The extension is currently in limited preview, available only to 1,000 Claude Max subscribers via a waitlist. Security is the main focus – prompt injection attacks are flagged as the top threat. To counter this, Anthropic is introducing permission systems and protective measures to reduce vulnerabilities.

Similar issues were previously exposed by Brave, which found that malicious instructions could be injected directly through website content in Perplexity’s Comet browser agent. Claude’s extension, however, shows progress compared to Anthropic’s earlier Computer Use tool, which had very limited capabilities.

Agentic browsing is still in its early stages, and vulnerabilities show security is far from solved. Still, Anthropic’s choice to test directly inside the world’s most widely used browser (Chrome) marks a shift from competitors building separate platforms like Comet and Dia. If the safeguards prove effective, Claude could become one of the first AI agents adopted at scale within everyday browsing.

In brief: Tech World Highlights

Tesla appealed a jury verdict that found it partially liable for a fatal crash involving Enhanced Autopilot, ordering $242.5 million in damages.
OpenAI plans to build a 1-gigawatt data center and open an office in India as part of its global “Stargate” infrastructure initiative, Bloomberg reports.
California startup Flip, once valued at $1 billion for its TikTok-style shopping and review app, has shut down operations.
Biotech firm Exelixis is laying off 130 workers and closing a Pennsylvania facility while consolidating its cancer therapy operations.
Novo Nordisk secured global rights to Replicate Bioscience’s self-replicating RNA technology in a deal worth up to $550 million, targeting obesity and diabetes therapies.